Abstract
43001 Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have